CXCR4 and acute myeloid leukemia: Lots of CXCR4 antagonist, such as plerixafor (Uy et al., 2012; Borthakur et al., 2020), LY2510924 (Boddu et al., 2018), BL-8040 (Borthakur et al., 2021), POL6326 (Chen et al., 2010), etc. have been applied in clinical trials in AML patients recently.